Main description:

This integrated book covers the entire spectrum of cancer biomarkers in development and clinical use. Predictive and prognostic markers are explored in the context of colon cancer, breast cancer, lung cancer, prostate cancer, and GIST. International experts provide insight into toxicity markers and surrogate markers. Attention is also given to biomarker assay development, validation, and strategies. A powerful tool for determining decisions on therapy, selecting drug regimens, monitoring the efficacy of treatment, and performing individualized surveillance, biomarkers represent the forefront of cancer research and treatment. As these technologies become increasingly available for clinical use, this book will be an essential resource for oncologists and translational researchers.

Contents:

Chapter 1 Predictive Markers in Clinical Development a) Colon Cancer (k ras) b) Breast Cancer (ER/PR, Her2) c) Lung Cancer (ERCC-1, EGFR mutant) d) Prostate Cancer (not sure?) e) GIST (exon 9 mutant Chapter 2 Prognostic Markers in Clinical Development f) Colon Cancer (signatures) g) Breast Cancer (oncotype) h) Lung Cancer i) Prostate Cancer j) GIST ckit mutant, PDGFR mutant Chapter 3 Toxicity Markers (UGT1A1, TS, MTHFR) Chapter 4 Surrogate Markers Chapter 5 Biomarker Assay Development and Validation Strategies a) clinical validation of biomarkers b) regulatory issues c) biomarkers of safe assessment and clinical pharmacology d) biomarker discovery strategies e) biomarker for go/no go decisions